|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ursodeoxycholic acid improves gastrointestinal motility defects in gallstone patients显示文摘AIM: To simultaneously evaluate the presence of defects in gallbladder and gastric emptying, as well as in intestinal transit in gallstone patients (GS) and the effect of chronic ursodeoxycholic acid (UDCA) administration on these parameters and on serum bile acids and clinical outcome in GS and controls (CTR). METHODS: After a standard liquid test meal, gallbla-dder and gastric emptying (by ultrasound), oroileal transit time (OITT) (by an immunoenzymatic technique) and serum bile acids (by HPLC) were evaluated before and after 3 mo of UDCA (12 mg/kg bw/d) or placebo administration in 10 symptomatic GS and 10 matched healthy CTR. RESULTS: OITT was longer in GS than in CTR (P < 0.0001); UDCA significantly reduced OITT in GS (P < 0.0001), but not in CTR. GS had longer gastric half-emptying time (t1/2) than CTR (P < 0.0044) at baseline; after UDCA, t1/2 significantly decreased (P < 0.006) in GS but not in CTR. Placebo administration had no effect on gastric emptying and intestinal transit in both GS and CTR. CONCLUSION: The gallstone patient has simultaneous multiple impairments of gallbladder and gastric emptying, as well as of intestinal transit. UDCA administration restores these defects in GS, without any effect in CTR. These results confirm the pathogenetic role of gastrointestinal motility in gallstone disease and suggest an additional mechanism of action for UDCA in reducing bile cholesterol supersaturation. | A Colecchia G Mazzella L Sandri F Azzaroli M Magliuolo P Simoni ML Bacchi-Reggiani E Roda D Festi | 2006 | World Journal of Gastroenterology2006，12，33： | 4 |
| 2 | Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis:A global survey of physicians'practice显示文摘AIM To examine treatment decisions of gastroenterologists regarding the choice of prescribing 5-aminosalycilates(5ASA) with corticosteroids(CS) versus corticosteroids alone for patients with active ulcerative colitis(UC). METHODS A cross-sectional questionnaire exploring physicians' attitude toward 5ASA + CS combination therapy vs CS alone was developed and validated. The questionnaire was distributed to gastroenterology experts in twelve countries in five continents. Respondents' agreement with stated treatment choices were assessed by standardized Likert scale. Background professional characteristics of respondents were analyzed for correlation with responses. RESULTS Six hundred and sixty-four questionnaires were distributed and 349 received(52.6% response rate). Of 340 eligible respondents, 221(65%) would continue 5ASA in a patient hospitalized for intravenous CS treatment due to a moderate-severe UC flare, while 108(32%) would stop the 5ASA(P < 0.001), and 11(3%) are undecided. Similarly, 62% would continue 5ASA in an out-patient starting oral CS. However, only 140/340(41%) would proactively start 5ASA in a hospitalized patient not receiving 5ASA before admission. Most(94%) physicians consider the safety profile of 5ASA as very good. Only 52% consider them inexpensive, 35% perceive them to be expensive and 12% are undecided. On multi-variable analysis, less years of practice and perception of a plausible additive mechanistic effect of 5ASA + CS were positively associated with the decision to continue 5ASA with CS. CONCLUSION Despite the absence of data supporting its benefit, most gastroenterologists endorse combination of 5ASA + CS for patients with active moderate-to-severe UC. Randomized controlled trials are needed to assess if 5ASA confer any benefit for these patients. | Shomron Ben-Horin Jane M Andrews Konstantinos H Katsanos Florian Rieder Flavio Steinwurz Konstantinos Karmiris Jae Hee Cheon Gordon William Moran Monica Cesarini Christian D Stone Doron Schwartz Marijana Protic Xavier Roblin Giulia Roda Min-Hu Chen Ofir Har-Noy Charles N Bernstein | 2017 | World Journal of Gastroenterology2017，23，16： | 3 |
| 3 | Separation techniques for bile salts analysis显示文摘 | RODA A PIAZZA F BARALDINI M | 1998 | J Chromatogr B1998，717，12： | 1 |
| 4 | Bio - and chemiluminescence in bioanalysis 显示文摘 | Roda A Pasini P Guardigli M | 2000 | Fresenius J Anal Chem2000，366，67： | 1 |
| 5 | Epilepsysurgery for tuberous sclerosis 显示文摘 | Romanelli P Verdecchia M Rodas R | 2004 | Pediatric Neurology2004，31，： | 1 |
| 6 | Anatomic and Hemodynamic Study of Anterior Communicating Artery Complex显示文摘 | Gonzale Llanos F Pascual J M Roda J M | 2002 | Neurocirugia2002，13，4： | 1 |
| 7 | Lysophosphatidic acid pretreatment prevents micromolaratorvas tat in-induced endothelial cell death and ensures thebeneficial effects of high-concentration statin therapy onendothelial gene express ion显示文摘 | Garrido JM1 Esteban M Roda 0 Alaminos M Sdnchez-MontesinosI | 2012 | Ann Vase Surg2012，26，4： | 1 |
| 8 | Preparation and characterization of ethanol-treated silk fibroin dense membranes for biomaterials application using waste silk fibers as raw material显示文摘 | NOGUEIRA G M RODAS A C D LEITE C A P | 2010 | Bio-Resource Technology2010，101，21： | 1 |
| 9 | Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer 显示文摘 | Frasson M Garcia-Granero E Roda D | 2011 | Cancer2011，117，： | 1 |
| 10 | Nano bioanalytical luminescence:F(o)rster-type energy transfer methods显示文摘 | Roda A Guardigli M Michelini E | 2009 | Anal BioanalChem2009，393，1： | 1 |
| 11 | High performance liquid chromatographic-electrospray mass spectrometric analysis of phenolic acids and aldehydes显示文摘 | Gioaccini A M Roda A Galletti G C | 1995 | J Chromatogr A1995，730，： | 1 |
| 12 | Bio-and chemilumi-nescence imaging in analytical chemistry 显示文摘 | Roda A Guardigli M Pasini P | 2005 | Anal ChirnActa2005，541，12： | 1 |
| 13 | Analytical approach for monitoring endocrine disrupting compounds in urban waste water treatment plants显示文摘 | RODA A MIRASOLI M MICHELINI E | 2006 | Anal Bio Anal Chem2006，385，： | 1 |
| 14 | Bioluminescence and chemiluminescence in drug screening显示文摘 | Roda A Guardigli M Pasini P | 2003 | Anal Bioanal Chem2003，377，5： | 1 |
| 15 | Separation techniques for bile salts analysis 显示文摘 | Roda A Piazza F Baraldini M | 1998 | J Chromatogr B Biomed Sci Appl1998，717，12： | 1 |
| 16 | Microtiter format for simultaneors multianalyte detection and development of a PCR chemiluminescent enzyme immunoassay for typing human papillomavirus DNA 显示文摘 | Roda A Mirasoli M Venturoli S | 2002 | Clin Chem2002，48，10： | 1 |
| 17 | Cylindrocladium blight of Eucalyptus grandis in Colombia 显示文摘 | Rodas C A Lombard L Gryzenhout M | 2005 | Australasian Plant Pathology2005，34，2： | 1 |
| 18 | Polyphasic study of wine Lactobacillus strains:taxonomic implications 显示文摘 | Rodas A M Ferrer S Pardo I | 2005 | International Journal of Systematic and Evolutionary Microbiology2005，55，： | 1 |
| 19 | Development and validation of a sensitive and fast chemiluminescent en- zyme immune assay for the detection of genetically modified maize显示文摘 | Roda A Mirasoli M Guardigli M | 2006 | Anal Chem2006，384，6： | 1 |
| 20 | Bio and chemiluminescence in bioanalysis显示文摘 | Roda A Pasini P Guardigli M | | 0，，06： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员